A practical framework for choosing e-signatures in global trials
Sonia Fischer, Director of Product Management, IQVIA, discusses the main considerations when to use QES or AES.
Comment & Opinion
MRSA therapeutics market to reach $1.8bn across 7MM in 2034
Can CNS trial momentum convert into late-stage evidence?
Narcolepsy market expected to reach $7.8bn across 7MM by 2035
ESC 2026: oral semaglutide shows lower 3-year CV risk than injectable in T2D
ESC 2026: Head-to-head study compares inclisiran and bempedoic acid
ESC 2026: enlicitide extends oral PCSK9 benefits beyond LDL-C lowering
ESC 2026: laroprovstat evaluated to close the LDL-C treatment gap
